

MONDAY 6 SEPTEMBER	
11.00am	Registration and Exhibition and Poster Area opens
1.00pm - 3.00pm	Opening Ceremony & Plenary: Innovations and Challenging Orthodoxy
	Grand 1 - 4 Chairs: Geoff McCaughan & Helen Tyrrell
1.00pm - 1.05pm	Welcome to the Land Speaker, Margaret Gardiner
1.05pm - 1.10pm	Welcome by Levinia Crooks, CEO, Australasian Society for HIV Medicine
1.10pm - 1.15pm	Introduction by Geoff McCaughan, Representative of the 2010 Viral Hepatitis Conference Partners
1.15pm - 1.20pm	Announcement of the Innovation Award Recipients, Greg Dore, President, Australasian Society for HIV Medicine
1.20pm - 1.45pm	Maria Prins, Senior Epidemiologist, Head Department of Research, Cluster Infectious Diseases, Health Service of Amsterdam, The Netherlands Changing times in hepatitis C epidemiology
1.45pm - 2.10pm	Edward Gane, Hepatologist, New Zealand Liver Transplant Unit, New Zealand New directions in hepatitis C therapy
2.10pm - 2.35pm	Helen Watchirs, ACT Human Rights and Discrimination Commissioner, ACT, Australia Human rights and discrimination issues related to blood borne viruses
2.35pm - 3.00pm	Robert Gish, Gastroenterologist, Medical Director, Liver Disease Management and Transplant Program, California Pacific Medical Center, California, United States of America New hepatitis B treatments: Long-term therapy: balancing the risk and benefits as we pursue sustained viral clearance
3.00pm - 3.30pm	Afternoon Tea in Exhibition and Poster Area, Grand Foyer

3.30pm - 5.00pm	The Shifting Focus of Hepatitis B Supported by Australian Government Department of Health & Ageing Grand 1 - 4 Chairs: Robert Gish & Nghi Phung	3.30pm - 5.00pm	HCC: The Problem is Now Grand 5 & 6 Chairs: Monica Robotin & Mariam Levy
3.30pm - 3.50pm	Benjamin Cowie, Epidemiologist, Victorian Infectious Diseases Service, Royal Melbourne Hospital, VIC, Australia Something old, something new: The epidemiology of hepatitis B in Australia	3.30pm - 3.50pm	Nick Shackel, Senior Lecturer, Medicine, Central Clinical School, Centenary Institute of Cancer Medicine & Cell Biology, University of Sydney, NSW, Australia Genomics is necessary to maximise treatment outcomes
3.50pm - 4.10pm	Edward Gane, Hepatologist, New Zealand Liver Transplant Unit, New Zealand Screening hepatitis B in the community: Effect on therapy uptake	3.50pm - 4.10pm	Rosie Thien, Lecturer, Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, NSW, Australia Epidemiological overview of hepatocellular carcinoma
4.10pm - 4.30pm	Kumar Visvanathan, Infectious Disease Physician, Monash Medical Centre, VIC, Australia Pathogenesis of hepatitis B infection	4.10pm - 4.30pm	Paul Gow, Deputy Director, Gastroenterology Unit, Austin Hospital, VIC, Australia Current treatment paradigms
4.30pm - 5.00pm	Discussion	4.30pm - 5.00pm	Discussion
5.00pm - 6.30pm	Welcome Reception & Poster Viewing Evening, Grand Foyer Supported by Roche Products		

TUESDAY 7 SEPTEMBER	
7.30am	Registration
7.30am - 9.00am	<p>Gilead Satellite Symposium, CHB treatment, endpoints and stopping rules. New agents, better outcomes... Presented by Prof Robert Gish</p> <p>Grand 5 & 6</p>
9.00am - 10.30am	<p>Maximising Our Current Knowledge</p> <p>Grand 1 - 4</p> <p>Chairs: Joe Torresi & Margaret Hellard</p>
9.00am - 9.30am	<p>Jacob George, Director, Storr Liver Unit, Westmead Millennium Institute of Medical Research, NSW, Australia</p> <p>Host genetics and treatment responses in chronic hepatitis C infection</p>
9.30am - 10.00am	<p>Carla Treloar, Head, Hepatitis C Program, Deputy Director, National Centre in HIV Social Research, NSW, Australia</p> <p>Tackling the fundamentals: Social inclusion and hepatitis C</p>
10.00am - 10.30am	<p>Scott L. Friedman, President, American Association for the Study of Liver Diseases, Fishberg and Professor of Medicine, Chief, Division of Liver Diseases, Mount Sinai School of Medicine, New York, United States of America</p> <p>Current approaches to anti-fibrotic therapies</p>
10.30am - 11.00am	Morning Tea in Exhibition and Poster Area, Grand Foyer

	Community & Social Research: Understanding Community		Clinical Medicine: Prediction of Hepatitis C Treatment Response		Epidemiology, Public Health & Prevention: Models, Mortality and Money - the "Big Picture" of Hepatitis C and Hepatitis B		Basic Science: Hepatitis Pathogenesis and Virology
11.00am - 12.30pm	Grand 1 & 2 Chairs: Annie Madden &	11.00am - 12.30pm	Grand 3 & 4 Chairs: Jacob George & Simone Strasser	11.00am - 12.30pm	Grand 6 Chairs: Mark Stoove & Emma McBryde	11.00am - 12.30pm	Grand 5 Chairs: David Anderson & Silvana Gaudieri
11.00am - 11.15am	McNeill H - Hep C: Take control - A chronic disease self management intervention for people with hepatitis C	11.00am - 11.15am	Grebely J - Potential role for IL28b genotype in treatment decision-making in recent hepatitis C virus infection	11.00am - 11.15am	Wilson D - Evaluating the cost-effectiveness of needle and syringe programs in Australia for preventing hepatitis C infection among people who inject drugs	11.00am - 11.15am	Prakoso E - Ductular reaction in hepatitis C recurrence post liver transplantation
11.15am - 11.30am	Crawford S - Ensuring research meets community expectation – The development of a community ratification process of research involving people who use drugs in NSW.	11.15am - 11.30am	Thompson A - IL28b polymorphism determines treatment response of patients with hepatitis C genotypes 2 or 3 who do not achieve a rapid virologic response	11.15am - 11.30am	Lauzon C - Change for the better: HIV and hepatitis C seroprevalence among attendees of New Zealand needle exchanges 2004-2009	11.15am - 11.30am	Walsh R - Novel ignar intrabody targeting the hepatitis B virus precore/core antigen
11.30am - 11.45pm	Cairnduff S - Engaging young Aboriginal people in hepatitis C health promotion	11.30am - 11.45am	Roberts S - Predicting SVR by combining early measurements of viral load with baseline characteristics including fibrosis score: Enhanced potential to individualise HCV treatment decisions.	11.30am - 11.45am	Thein R - Epidemiological and economic impact of potential increased hepatitis C treatment uptake in Australia	11.30am - 11.45am	Torresi J - Differential modulation of stat/socs signaling in HBV/HCV-coinfection
11.45am - 12.00pm	O'Callaghan S - The wellbeing weekend: A holistic approach to living well with hepatitis C	11.45am - 12.00pm	Baleriola C - Impact of low level HCV viremia at week 24 on HCV treatment response in genotype 1 patients	11.45am - 12.00pm	Matser A - The effect of HCV treatment and HIV coinfection on the future disease burden of hepatitis C among injecting drug users in Amsterdam	11.45am - 12.00am	Ratnam D - Toll like receptor agonist induced IFN - Responses by natural killer cells in chronic hepatitis B infection
12.00pm - 12.15pm	Treloar C - Sydney Egyptian communities understanding of HCV, their knowledge of virus transmission, attitudes towards HCV and treatment.	12.00pm - 12.15pm	Sievert B - Significant hemoglobin (HB) decline during pegylated interferon and ribavirin therapy in HCV genotype 1 is associated with sustained virological response (SVR): An analysis from the chariot study	12.00pm - 12.15pm	Gidding H - Trends in all cause and liver-related hospital admissions in people notified with hepatitis B and C in New South Wales, Australia	12.00pm - 12.15pm	Crane M - LPS: Immune activation and liver disease in HIV-HBV co-infection
12.15pm - 12.30pm	Wang J - Knowledge & prevention: A hepatitis B survey in the Chinese community	12.15pm - 12.30pm	Dore G - Low virological response and high relapse rates in hepatitis C genotype 1 patient's with advanced fibrosis despite adequate therapeutic dosing	12.15pm - 12.30pm	Walter S - Causes of death after diagnosis with hepatitis B or C: 1992-2006	12.15pm - 12.30pm	Littlejohn M - Evolution of HBV during HBV-active HAART

12.30pm - 1.30pm	Lunch in Exhibition and Poster Area, Grand Foyer						
1.30pm - 3.00pm	Management and Treatment of Injecting Drug Users Grand 1 & 2 Chairs: Maria Prins & Jacqui Richmond	1.30pm - 3.00pm	Moving forward with Hepatitis B Policy and Practice Grand 3 & 4 Chairs: Benjamin Cowie & Jack Wallace	1.30pm - 3.00pm	Current Challenges in HCV Therapies Grand 6 Chairs: Amany Zekry & Stuart Roberts	1.30pm - 3.00pm	Hepatitis C, Immunity and Pathogenesis Grand 5 Chairs: Peter Angus & Andrew Lloyd
1.30pm - 1.50pm	Margaret Hellard, Head, Centre for Population Health, Burnet Institute, VIC, Australia Myths and reality: Managing IDUs with hepatitis C	1.30pm - 1.50pm	Jack Wallace, Research Fellow, Australian Research Centre in Sex, Health and Society, Latrobe University, VIC, Australia and Benjamin Cowie, Epidemiologist, Victorian Infectious Diseases Service, Royal Melbourne Hospital, VIC, Australia Setting the scene: A social and community perspective and Setting the scene: An epidemiology and public health perspective	1.30pm - 1.50pm	William Sievert, Director, Gastrointestinal and Liver Unit, Monash Medical Centre and Dandenong Hospital, VIC, Australia Is retreatment worthwhile	1.30pm - 1.50pm	David Bowen, Senior Lecturer, Medicine, Central Clinical School, Centenary Institute, University of Sydney, NSW, Australia Immunological determinants of HCV control and clearance
1.50pm - 2.10pm	Annie Madden, Executive Officer, Australian Injecting & Illicit Drug Users League Hepatitis C treatment and injecting drug users: On a tightrope without a safety net?	1.50pm - 2.10pm	Lisa Ryan, Manager, Harm Minimisation, NSW Department of Health, NSW, Australia Implementation of the first national hepatitis B strategy: A NSW perspective	1.50pm - 2.10pm	Simone Strasser, Royal Prince Alfred Hospital, A W Morrow Gastroenterology and Liver Centre, NSW, Australia Treating advanced disease	1.50pm - 2.10pm	Scott L. Friedman, President, American Assn. for the Study of Liver Diseases, Fishberg and Professor of Medicine, Chief, Division of Liver Diseases, Mount Sinai School of Medicine, New York, United States of America Basic mechanisms of fibrosis

2.10pm - 2.30pm	<p>Greg Dore, Professor and Head, Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, NSW, Australia</p> <p>Partnerships to enhance hepatitis C treatment uptake and outcomes among injecting drug users</p>	2.10pm - 2.30pm	<p>Lisa Maher, Professor and Head, Viral Hepatitis Epidemiology and Prevention Program, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, NSW, Australia</p> <p>Hepatitis B and people who inject drugs: challenges, innovations and opportunities</p>	2.10pm - 2.30pm	<p>Paul Desmond, Director, Department of Gastroenterology, St. Vincent's Hospital, VIC, Australia</p> <p>Personalising therapy</p>	2.10pm - 2.30pm	<p>Eric Gowans, Executive Director, Women's and Children's Health Research Institute, SA, Australia</p> <p>Vaccine prospects for HCV</p>
2.30pm - 3.00pm	Discussion	2.30pm - 2.50pm	<p>Steven Tipper, Manager, Scientific Development, Research Strategy & Scientific Development Unit, The Cancer Council NSW, NSW, Australia</p> <p>The B positive project: challenges in CALD community engagement and GP education</p>	2.30pm - 3.00pm	Discussion	2.30pm - 3.00pm	Discussion
2.50pm - 3.00pm		2.50pm - 3.00pm	Discussion				
3.00pm - 3.30pm	<p>Afternoon Tea in Exhibition and Poster Area, Grand Foyer Multi Media Presentation, Is treatment right for you?, Louise Smith, Grand 6</p>						

3.30pm - 5.00pm	Community & Social Research: Cultures, Communities and Hepatitis C Treatment	3.30pm - 5.00pm	Epidemiology, Public Health & Prevention: Hepatitis B and Hepatitis C Transmission and Clearance – What's New	3.30pm - 5.00pm	Clinical Medicine: Across the Spectrum, Post Populations	3.30pm - 5.00pm	Basic Science: Immunology of Hepatitis Viruses
	Grand 1 & 2 Chairs: Jim Hyde & Max Mopwood		Grand 3 & 4 Chairs: Lisa Maher & Jason Grebely		Grand 6 Chairs: Paul Desmond & Bill Sievert		Grand 5 Chairs: Eric Gowans & Mandvi Bharadwaj
3.30pm - 3.45pm	Honey C - The changing arrangements for access to hepatitis C treatment and care services across NSW	3.30pm - 3.45pm	Winter R - Prevalence and incidence of hepatitis B virus exposure and vaccination in a Melbourne cohort of people who inject drugs	3.30pm - 3.45pm	Thompson A - IL28b polymorphism, jaundice during acute HCV infection, and spontaneous clearance in the German anti-d cohort	3.30pm - 3.45pm	Johnson D - Novel adjuvants to increase humoral neutralising antibody and cellular immune responses to recombinant mammalian cell derived hepatitis C virus-like-particles
3.45pm - 4.00pm	McNally S - Share care: Do we need a model?	3.45pm - 4.00pm	Sacks-Davis R - Elispot testing shows very few people who inject drugs avoid hepatitis C virus exposure	3.45pm - 4.00pm	Matthews G - Differences in early virological decline in individuals treated within the Australian trial in acute HCV suggest a potential benefit for the use of ribavirin	3.45pm - 4.00pm	Grant E - Novel measures for induction of effective hepatitis C virus-specific T cell immunity
4.00pm - 4.15pm	Brener L - Evaluation of a hepatitis C community clinic in Christchurch, New Zealand	4.00pm - 4.15pm	Lloyd A - HCV incidence and infection outcome in a follow-up study of high-risk IDU prison inmates	4.00pm - 4.15pm	Manoharan S - Lamivudine in the last trimester of pregnancy for prevention of HBV transmission: Post-partum hepatic flares and development of genotypic nucleos(t)ide resistance	4.00pm - 4.15pm	Flynn J - Altered cytokine responses in HCV-infected subjects treated with interferon-alpha
4.15pm - 4.30pm	Te Au H - Hepatitis C resource centre Otago and the local needle exchange started providing blood testing on site	4.15pm - 4.30pm	Grebely J - Hepatitis C virus genotype and female sex are independently associated with spontaneous clearance during acute infection - findings from an international collaboration (INC3)	4.15pm - 4.30pm	Hajarizadeh B - Comparing the cost-effectiveness of three- versus two-dose vaccination schedule against hepatitis b in adolescents. Experience of a developing country	4.15pm - 4.30pm	Wilson R - Genotype-specific suppression of TIR-mediated innate immunity by the hepatitis B E antigen
4.30pm - 4.45pm	Everingham H - Enhanced treatment for hepatitis C in opioid substitution settings (ethos) - exploring the role of peer support in the delivery of hepatitis C treatment	4.30pm - 4.45pm	Hellard M - Hepatitis C transmission and clearance in a cohort of injecting drug users – A highly dynamic process	4.30pm - 4.45pm	Carville K - Does hepbhelp help? An evaluation of a web-based resource for the care of patients with newly diagnosed chronic hepatitis B in Victoria	4.30pm - 4.45pm	Llyod A - Evaluation of potentially protective immunity in highly exposed, but uninfected prison inmates in the hits study
4.45pm - 5.00pm	Rance J - The politics of place(ment): Treating hepatitis C within opiate substitution	4.45pm - 5.00pm	Pham S - Infection with multiple HCV strains in a prison cohort of seronegative injecting drug users	4.45pm - 5.00pm	Shadur B - The changing epidemiology of hepatitis D in Australia: Challenging our clinical response	4.45pm - 5.00pm	Bharadwaj M - CTL escape by evasion of T cell recognition in hepatitis c virus infection
7.00pm	Conference Dinner, The Carousel, Albert Park						

WEDNESDAY 8 SEPTEMBER							
7.30am	Registration						
9.00am - 10.30am	Community & Social Research: The Cutting Edge of Social Research	9.00am - 10.30am	Epidemiology, Public Health & Prevention: Prevention, Prison & Patient Models of Care	9.00am - 10.30am	Clinical Medicine: Enhancing Hepatitis C Treatment and Care	9.00am - 10.30am	Basic Science: Host Genetics and Cell Biology
	Grand 1 & 2 Chairs: Meredith Temple-Smith & Sandra Gregson		Grand 3 & 4 Chairs: Sally Bell & Michael Levy		Grand 6 Chairs: Fran Bramwell		Grand 5 Chairs: Joe Toressi & Alex Thompson
9.00am - 9.15am	Fry M - Rising to the challenge of self-managing hepatitis C: The mixed impact of disclosure	9.00am - 9.15am	Stoove M - Intraprison injecting risk practices and post-release blood borne virus transmission: Results from a post-prison release cohort study of people who inject drugs	9.00am - 9.15am	Salehi Alavi M - Impact of pegylated interferon alfa-2a treatment on depression during recent HCV infection: the Australian Trial in Acute Hepatitis C (ATAHC)	9.00am - 9.15am	Thompson A - IL28B polymorphism is associated with intrahepatic ISG expression in patients with chronic HCV infection
9.15am - 9.30am	Seear K - The sneaky virus: Constituting hepatitis C through health promotions literature	9.15am - 9.30am	Huber C - Maximising hepatitis C prevention in hard to reach populations utilising the pharmacy sector	9.15am - 9.30am	Blacklaws H - Irritability: An under-appreciated side effect of interferon treatment for chronic hepatitis C?	9.15am - 9.30am	Suppiah V - Host genetics and treatment response in chronic hepatitis C interferon and ribavirin therapy
9.30am - 9.45am	Wallace J - Health and security - Mixing oil and water? Regulating hepatitis C prevention in prisons	9.30am - 9.45am	Deacon R - Correlates of hepatitis B vaccination status among injecting drug users: A comparison of eligible and ineligible participants in the havit trial	9.30am - 9.45am	Ferguson L - Providing an HCV service in a busy drug and alcohol service, without additional resources	9.30am - 9.45am	D'Avigdor W - Correlation of miRNA and mRNA expression profiles differentiating hepatitis C (HCV) genotypes 1 and 3 liver injury
9.45am - 10.00am	Wilson H - Perception of hepatitis C risk among injecting drug users who obtain injecting equipment from pharmacies in Western Australia	9.45am - 10.00am	Newley N - Promotion and information with respect (pair) project	9.45am - 10.00am	Tenison F - Onsite access to specialist hepatitis C medical clinics - Outcomes in outreach hepatitis C services in community based clinics	9.45am - 10.00am	Nachbur U - Hepatitis B virus inhibits ciap1 and increases sensitivity to TNF-alpha in primary hepatocytes
10.00am - 10.15am	Newland J - Peer distribution: A pre-existing, effective and illegal model of sterile injection equipment distribution in NSW	10.00am - 10.15am	Gillman A - Assessment and treatment of chronic hepatitis C virus (HCV) infection in a prospective, observational cohort of injection drug users (IDUS): the ethos cohort	10.00am - 10.15am	Russell D - Equitable access to hepatitis C treatment: Establishing and maintaining an HCV clinic in a correctional facility	10.00am - 10.15am	Parsian H - Comparison of five liver fibrosis indexes with serum levels of laminin and n-terminal peptide of procollagen type III in chronic hepatitis patients
10.15am - 10.30am	Paquette D - Who doesn't get captured by a respondent-driven sampling survey of people who inject drugs?	10.15am - 10.30am	Douglas J - Development and evaluation of a nurse-led model of care for treatment of prisoners with chronic hepatitis C	10.15am - 10.30am	Baker D - Hepatitis C treatment initiation in primary care	10.15am - 10.30am	Discussion

10.30am - 11.00am	Morning Tea in Exhibition and Poster Area, Grand Foyer						
	Tackling Hepatitis C in Challenging Environments		Living with, Support and Treatment of Hepatitis C		Viral Hepatitis and HIV Co-Infection		Host Metabolism, Genetics and Viral Pathogenesis
11.00am - 12.30pm	Grand 1 & 2 Chairs: Chris Cunningham & Sonam Paljor	11.00am - 12.30pm	Grand 3 & 4 Chairs: Nadia Gavin & Tracey Jones	11.00am - 12.30pm	Grand 6 Chairs: David Iser & Greg Dore	11.00am - 12.30pm	Grand 5 Chairs: Scott Friedman & Nick Shackel
11.00am - 11.20am	Michael Levy, Director, Corrections Health Program, ACT, Australia Human rights, prison and injecting drug use; Commissioning the health service in a human rights compliant prison.	11.00am - 11.20am	Max Hopwood, Research Fellow, National Centre in HIV Social Research, NSW, Australia Support for people with hepatitis C: What is it, where do you get it and does it make any difference?	11.00am - 11.20am	Janaki Amin, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, NSW, Australia HIV and viral hepatitis coinfection: burden of disease	11.00am - 11.20am	Amany Zekry, Senior Lecturer, St George Clinical School, Faculty of Medicine, UNSW, NSW, Australia The effect of obesity on inflammatory response in hepatitis C
11.20am - 11.40am	Stephen McNally, Senior Research Fellow, Australian Research Centre in Sex, Health and Society, La Trobe University, VIC, Australia Recognising and responding to hepatitis C in Indigenous communities	11.20am - 11.40am	Suzanne Fraser, Centre for Women's Studies and Gender Research, School of Political and Social Inquiry, Monash University, VIC, Australia Social constructions	11.20am - 11.40am	Gail Matthews, Senior Lecturer, Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, NSW, Australia HIV/HCV co infection –transmission to treatment	11.20am - 11.40am	Silvana Gaudieri, Associate Professor, School of Anatomy & Human Biology & Centre for Forensics, University of Western Australia, WA, Australia Host genetics and HCV disease progression

11.40am - 12.00pm	<p>Fiona Poeder, Hepatitis C Program Manager, Australian Injecting and Illicit Drug Users' League, ACT, Australia</p> <p>Peers in mainstream organisations 'how can you be a 'peer' if you're not allowed to identify as a drug user?'</p>	11.40am - 12.00pm	<p>Robert Batey, Clinical Professor of Medicine, Sydney University, Senior Staff Specialist, Drug Health Services, RPAH Sydney, NSW, Australia</p> <p>Treating HCV in out of the way places; Who is doing what and do they need to?</p>	11.40am - 12.00pm	<p>Sharon Lewin, Director, Infectious Diseases Unit, Alfred Hospital; Professor of Medicine, Monash University; Co-head, Centre for Virology, Burnet Institute, Melbourne, VIC, Australia</p> <p>Pathogenesis of HIV-HBV co-infection: Implications for treatment strategies</p>	11.40am - 12.00pm	<p>Elizabeth Powell, Associate Professor, University of Queensland and the Princess Alexandra Hospital, QLD, Australia</p> <p>Disease progression in HCV - Role of impaired hepatocyte replication, progenitor cells and host metabolic factors</p>
12.00pm - 12.30pm	<p>Panel Discussion: Facilitator, Helen McNeill, CEO, Hepatitis Victoria, VIC, Australia Panellists: Michael Levy; Stephen McNally; Fiona Poeder; Jenny Kelsall, Team Leader, BBV Education & Support, Harm Reduction Victoria; Sione Crawford, Community Programs Worker, NSW Users and AIDS Association Ross Morgan, Hepatitis Victoria</p>	12.00pm - 12.30pm	Discussion	12.00pm - 12.20pm	Discussion	12.00pm - 12.30pm	Discussion
		12.20pm - 12.30pm		Co-infection HIV & Viral Hepatitis: A guide for Clinical Management, Resource Launch,			
wford	Lunch in Exhibition and Poster Area, Grand Foyer						

1.30pm - 3.30pm	Closing Session: Moving Forward - Challenges for the Next Decade
1.30pm - 1.55pm	Grand 1 - 4 Chairs: Carla Treloar & John Hornell
1.30pm - 1.55pm	Michael Kidd, Executive Dean of Health, Flinders University, South Australia and Chair of the Australian Government's Ministerial Advisory Committee on Blood Borne Viruses and Sexually Transmissible Infections, South Australia, Australia Moving forward, policy into program
1.55pm - 2.20pm	Maria Prins, Senior Epidemiologist, Head Department of Research, Cluster Infectious Diseases, Health Service of Amsterdam, The Netherlands Solving the key public health challenges in hepatitis C
2.20pm - 2.45pm	Stephen Locarnini, Professor, Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, VIC, Australia Drug resistance in hepatitis B has been defeated only to be replaced with hepatitis C
2.45pm - 3.10pm	Chris Cunningham, Director, Research Centre for Māori Health & Development, College of Humanities and Social Sciences, Massey University, New Zealand Hepatitis B, policy into program
3.10pm - 3.20pm	Closing Remarks: Greg Dore, Representative of the 2010 Viral Hepatitis Conference Partners
3.20pm - 3.30pm	Presentation of the next conference: 8th Australasian Viral Hepatitis Conference 2012
3.30pm	Conference Close